Sandoz adds to vision care options with the listing of biosimilar aflibercept

New Stories

• Sandoz adds to vision care options with the listing of biosimilar aflibercept

  February 2, 2026 -

• PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history

  February 2, 2026 - - Australian Biotech

• Genetic Signatures appoints seasoned life sciences executive as CEO

  February 2, 2026 - - Australian Biotech

• EMA decision clears regulatory path for Argenica’s lead stroke drug in Europe

  February 2, 2026 - - Australian Biotech

• Recce Pharmaceuticals deepens US partnership to advance burn wound treatment

  February 2, 2026 - - Australian Biotech

• Another potential turning point for immunotherapy access in Australia

  February 1, 2026 - - Latest News

• An announcement that cost more than the listing, because it would have actually cost something

  February 1, 2026 - - Latest News